Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial

Aim: The APHINITY trial showed that adding adjuvant pertuzumab (P) to trastuzumab and chemotherapy, compared with adding placebo (Pla), significantly improved invasive disease-free survival (IDFS) for patients with HER2+ early breast cancer both overall and for the node-positive (N+) cohort. We expl...

Full description

Bibliographic Details
Main Authors: APHINITY Steering Committee and Investigators (Author), Bines, J. (Author), Caballero, C. (Author), Cameron, D. (Author), Cardoso, F. (Author), Clark, E. (Author), Cole, B.F (Author), de Azambuja, E. (Author), Frank, E. (Author), Fumagalli, D. (Author), Gelber, R.D (Author), Heeson, S. (Author), Kiermaier, A. (Author), Krop, I. (Author), Loi, S. (Author), Loibl, S. (Author), Piccart-Gebhart, M. (Author), Procter, M. (Author), Restuccia, E. (Author), Salgado, R. (Author), Tjan-Heijnen, V. (Author), Wang, X.V (Author)
Format: Article
Language:English
Published: Elsevier Ltd 2022
Subjects:
Online Access:View Fulltext in Publisher